Fabric Genomics (formerly Omicia)

High-Level Overview

Fabric Genomics (formerly Omicia) develops AI-driven clinical decision support software for genomic data analysis, enabling accurate diagnoses in hereditary diseases, oncology, and rare disorders. Its Enterprise Platform processes whole genomes, exomes, and gene panels for commercial clinical labs, hospital systems, country-sequencing programs, and research institutions, delivering high diagnostic yields (up to 54% causative candidates) and rapid turnaround (under 1 hour for whole genomes).[1][2][5] The company serves leading organizations like Cincinnati Children’s, InterMountain, and Rady Children’s Institute, solving the challenge of scalable, precise genomic interpretation to advance precision medicine.[2][5] Acquired by GeneDx Holdings in April 2025 for $33M–$84M, Fabric maintains operational independence while gaining commercial backing, with total funding raised of $31.43M prior to acquisition.[1][2]

Origin Story

Fabric Genomics was founded in 2009 in Oakland, California, by Martin Reese, Ph.D. (co-founder, President, and CEO), Edward Kiruluta (co-founder), John Stuelpnagel, and Paul Billings, M.D., Ph.D. (co-founder and Acting Chief Medical Officer), with a vision to generate clinical insights from genomic analysis using AI and machine learning.[1][2][3][5][6] Initially focused on research tools, the company pivoted to clinical applications after raising an $8.3M Series A in December 2013.[2] Pivotal moments included selection for the UK's 100,000 Genomes Project in 2015, a $23M Series B in 2016, oncology expansion in 2017, and the launch of its scalable AI variant classification engine, ACE, in 2019—building early traction with over 1,000 academic and clinical users worldwide.[1][2]

Core Differentiators

• AI-Powered Accuracy: GEM algorithm ranks 98% of causal variants in the top 5 for rare diseases; ACMG-compliant classification validated across >50,000 variants, with yields up to 54%.[2][5]
• Speed and Efficiency: Whole genome analysis in <1 hour; 10x more cases per team; average 15-minute clinical review time; API integration with LIMS/EMR for optimized workflows.[1][2][5]
• Scalability and Versatility: End-to-end NGS platform for rare disease, hereditary risk, oncology, and newborn screening; supports decentralized testing with centralized intelligence.[1][4][5]
• Comprehensive Services: Rapid onboarding (4 weeks); lab validation, panel curation, SOP design, interpretation, and signout; licensed by dozens of top hospitals and labs.[2][5]

Role in the Broader Tech Landscape

Fabric Genomics rides the genomics and precision medicine wave, fueled by falling sequencing costs, AI advancements, and demand for rapid diagnostics in NICUs, oncology, and global newborn screening programs.[1][2][5] Timing aligns with post-2020 NGS adoption surges and regulatory pushes like Genomics England, positioning Fabric to enable large-scale programs amid a 2.8 million U.S. children with rare disorders.[1][4] Market forces favoring it include AI's role in variant interpretation bottlenecks and partnerships (e.g., Oxford Nanopore for pediatric WGS), influencing the ecosystem by standardizing AI-driven analysis for 1,000+ institutions and accelerating decentralized genomic testing.[2][4][5]

Quick Take & Future Outlook

As a GeneDx subsidiary, Fabric will likely expand neonatal testing, gNBS worldwide, and oncology/trial matching, leveraging parental resources for global scale.[1] Trends like AI-enhanced NGS, regulatory harmonization, and population screening will propel growth, evolving its influence from software provider to precision medicine enabler. This builds on its trailblazing foundation, ensuring genomic insights drive standard care.[2][5]